How did you feel about this article?
Pfizer Vaccines against Covid-19 | Photo: Américo Antonio / SESA
The US drug regulatory agency on Monday (23) granted final approval of the Pfizer / BioNTech vaccine against Covid-19 in the country. The FDA (Food and Drug Administration) had already authorized the emergency use of the product last December.
From now on, the vaccine will be marketed under the name Comirnaty, for the prevention of Covid-19 in people aged 16 and over. Emergency use for adolescents between 12 and 15 years old is still valid.
“As the first FDA-approved Covid-19 vaccine, the public can be very confident that this vaccine meets the high standards of safety, efficacy and build quality that the FDA demands of an approved product,” said said Janet Woodcock of the FDA. She said the agency hopes the final vaccine approval will generate more confidence in the population, bringing more people to vaccination posts.
“Today’s milestone brings us one step closer to changing the course of this pandemic in the United States,” she said. More than 170 million Americans have completed their Covid-19 vaccination schedule, or 51% of the population.
The vaccination campaign slowed in the United States between April and July. The increase in Covid-19 cases by the Delta variant has pushed more people to get vaccinated since last month, but even so, the number of doses applied per day is still well below the peak recorded in April.